The acquisition of sporadic biallelic TP53 mutations in SDS is clearly important clinically and biologically for clonal progression and transformation to MDS and is a poor prognostic indicator (Lindsley et al., 2017). The gene discussed is TP53; the disease is myelodysplastic syndrome.